Cardinal Health is aiming for 13 to 15 percent adjusted EPS growth in fiscal 2027, driven by momentum in its specialty segment and investments in oncology, urology, and autoimmune care.
Ireland’s cell therapy industry is growing quickly, but nearly all detachable activation beads are imported. Rising GMP-grade demand and new allogeneic therapies are reshaping the market, but supply chain risks persist.
Gujarat Themis Biosyn Limited has closed its Rs 1,200 crore deal to acquire MicroBiopharm Japan, gaining new biologics capabilities and a direct presence in regulated global markets.
Holtec Nuclear abruptly postponed its $825 million IPO while Nscale filed for a potential $2 billion offering and Electra Therapeutics suffered a rare biotech IPO drop.
North Carolina’s life sciences sector is taking a measured approach to growth, favoring smaller, risk-managed deals and targeted expansions, while a few major players make billion-dollar commitments.
Dualitas Therapeutics has signed a $36.5 million upfront agreement with Roche for access to its DualScreen Bispecific Discovery Engine, with total payments that could reach $1 billion.
SK Biopharmaceuticals has signed a licensing and equity agreement with 1ST Biotherapeutics, gaining exclusive global rights to a preclinical Parkinson's disease candidate with a dual-inhibition mechanism.
